Publications by authors named "Thomas A Abrams"

Claim this Profile
R
Racial and ethnic differences in treatment and survival for hepatocellular carcinoma patients undergoing systemic therapy.
Kelsey S Lau-Min, Angela C Tramontano, Franklin Iheanacho, Thomas Adam Abrams, Christopher R Manz

JNCI Cancer Spectr· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.
Rishi Surana, Micaela Morgado, Ashwin Somasundaram, Bruno Bockorny, Colin D Weekes, Thomas A Abrams

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changing treatment patterns for hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results-Medicare study.
Franklin Iheanacho, Angela C Tramontano, Thomas Adam Abrams, Christopher R Manz

Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer.
Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Juan W Valle, Chigusa Morizane, Thomas A Abrams

Future Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab.
Ryan J Park, Milan Parikh, Leon Pappas, Moshe Sade-Feldman, Anupriya S Kulkarni, Thomas A Abrams

medRxiv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.
Paul E Oberstein, Andressa Dias Costa, Emily A Kawaler, Victoire Cardot-Ruffino, Osama E Rahma, Thomas A Abrams

Cancer Immunol Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma.
Harshabad Singh, Kristen E Lowder, Kevin Kapner, Ronan J Kelly, Hui Zheng, Thomas A Abrams

Nat Commun· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
Harshabad Singh, Pranshu Sahgal, Kevin Kapner, Steven M Corsello, Hersh Gupta, Thomas A Abrams

Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer.
Lestat R Ali, Patrick J Lenehan, Victoire Cardot-Ruffino, Andressa Dias Costa, Matthew H G Katz, Thomas A Abrams

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.
Brandon M Huffman, Harshabad Singh, Lestat R Ali, Nora Horick, S Jennifer Wang, Thomas A Abrams

J Immunother Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Brandon M Huffman, Hanrong Feng, Kalindi Parmar, Junning Wang, Kevin S Kapner, Thomas A Abrams

Clin Cancer Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can MRI features predict clinically relevant hepatocellular carcinoma genetic subtypes?
Xiaoyang Liu, Yang Guo, Lei Zhao, Joseph Misdraji, Tina Kapur, Thomas A Abrams

Abdom Radiol (NY)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
Victoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, S Jennifer Wang, Lauren K Brais, Thomas A Abrams

J Immunother Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined PD-1, BRAF and MEK inhibition in BRAF colorectal cancer: a phase 2 trial.
Jun Tian, Jonathan H Chen, Sherry X Chao, Karin Pelka, Marios Giannakis, Thomas A Abrams

Nat Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer.
Rachel B Keller, Tali Mazor, Lynette Sholl, Andrew J Aguirre, Harshabad Singh, Thomas A Abrams

JCO Precis Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma.
Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Juan W Valle, Chigusa Morizane, Thomas A Abrams

N Engl J Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gallstones and risk of cancers of the liver, biliary tract and pancreas: a prospective study within two U.S. cohorts.
Xiao Luo, Wanshui Yang, Amit D Joshi, Kana Wu, Tracey G Simon, Thomas A Abrams

Br J Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma.
Bruno Bockorny, Andrea J Bullock, Thomas A Abrams, Salomao Faintuch, David C Alsop

Dig Dis Sci· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study.
Justin C Brown, Elizabeth Brighton, Nancy Campbell, Nadine J McCleary, Thomas A Abrams

BMJ Open Sport Exerc Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.
James M Cleary, Srivatsan Raghavan, Qibiao Wu, Yvonne Y Li, Liam F Spurr, Thomas A Abrams

Cancer Discov· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial.
Justin C Brown, Sui Zhang, Jennifer A Ligibel, Melinda L Irwin, Lee W Jones, Thomas A Abrams

Cancer Prev Res (Phila)· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Lipika Goyal, Cynthia Sirard, Michael Schrag, Michael H Kagey, Jennifer R Eads, Thomas A Abrams

Clin Cancer Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of High-Dose vs Standard-Dose Vitamin D Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial.
Justin C Brown, Michael H Rosenthal, Chao Ma, Sui Zhang, Halla S Nimeiri, Thomas A Abrams

Cancers (Basel)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer.
Lipika Goyal, Surendra Pal Chaudhary, Eunice L Kwak, Thomas A Abrams, Amanda N Carpenter

Invest New Drugs· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial.
Kimmie Ng, Halla S Nimeiri, Nadine J McCleary, Thomas A Abrams, Matthew B Yurgelun

JAMA· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis